These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
101 related articles for article (PubMed ID: 12400584)
21. New risk information on IBS drug Zelnorm. FDA Consum; 2004; 38(4):6. PubMed ID: 15346569 [No Abstract] [Full Text] [Related]
22. New drug for women with irritable bowel syndrome. Mayo Clin Health Lett; 2003 Dec; 21(12):4. PubMed ID: 14971349 [No Abstract] [Full Text] [Related]
25. Grappling with the quality of life. Patients, FDA and drug companies struggle to link therapies with well-being. Lewis C FDA Consum; 2001; 35(2):30-5. PubMed ID: 11444246 [No Abstract] [Full Text] [Related]
26. Alosetron to return to market. Young D Am J Health Syst Pharm; 2002 Jul; 59(14):1323-4. PubMed ID: 12132555 [No Abstract] [Full Text] [Related]
27. New drug approved for irritable bowel syndrome in women. Mayo Clin Womens Healthsource; 2004 Feb; 8(2):3. PubMed ID: 14722489 [No Abstract] [Full Text] [Related]
28. Irritable bowel syndrome: new approaches to its pharmacological management. Tougas G Can J Gastroenterol; 2001 Oct; 15 Suppl B():12B-13B. PubMed ID: 11694909 [TBL] [Abstract][Full Text] [Related]
29. Tegaserod treatment for IBS: a model of indirect costs. Smith DG; Barghout V; Kahler KH Am J Manag Care; 2005 Apr; 11(1 Suppl):S43-50. PubMed ID: 15926763 [TBL] [Abstract][Full Text] [Related]
30. Lotronex and the FDA: a fatal erosion of integrity. Horton R Lancet; 2001 May; 357(9268):1544-5. PubMed ID: 11377636 [No Abstract] [Full Text] [Related]
31. [Tegaserod in treatment of women with irritable bowel syndrome]. Munck LK; Ainsworth MA Ugeskr Laeger; 2007 Jun; 169(23):2190-2. PubMed ID: 17592683 [TBL] [Abstract][Full Text] [Related]
32. [Symptomatic therapy of irritable bowel syndrome. Which drug for which symptoms?]. Madisch A; Hotz J MMW Fortschr Med; 2001 Sep; 143(39):28-30. PubMed ID: 11680924 [TBL] [Abstract][Full Text] [Related]
33. Tegaserod for constipation-predominant irritable bowel syndrome. Kale-Pradhan PB; Wilhelm SM Pharmacotherapy; 2007 Feb; 27(2):267-77. PubMed ID: 17253916 [TBL] [Abstract][Full Text] [Related]
34. [Comparative study of Kaologeais and Smectite in the treatment of colopathies]. Dietsch R; Bonneville B Med Chir Dig; 1981; 10(6):549-51. PubMed ID: 7311645 [No Abstract] [Full Text] [Related]
35. Effect of tegaserod on colonic transit time in male patients with constipation-predominant irritable bowel syndrome. Harish K; Hazeena K; Thomas V; Kumar S; Jose T; Narayanan P J Gastroenterol Hepatol; 2007 Aug; 22(8):1183-9. PubMed ID: 17688659 [TBL] [Abstract][Full Text] [Related]
36. FDA advisers warn of more deaths if drug is relaunched. Moynihan R BMJ; 2002 Sep; 325(7364):561. PubMed ID: 12228121 [No Abstract] [Full Text] [Related]
37. At last--a treatment for IBS beyond placebo. Guda N; Vaki N Am J Gastroenterol; 2003 May; 98(5):1195-6. PubMed ID: 12830818 [No Abstract] [Full Text] [Related]
38. [The effect of Kaologeais in spastic colonic diseases]. Heraud M Med Chir Dig; 1979; 8(3):263-5. PubMed ID: 534010 [No Abstract] [Full Text] [Related]
39. Access options for withdrawn motility-modifying agents. Jones MP Am J Gastroenterol; 2002 Sep; 97(9):2184-8. PubMed ID: 12358230 [TBL] [Abstract][Full Text] [Related]
40. Budget impact of tegaserod on a managed care organization formulary. Bloom MA; Barghout V; Kahler KH; Bentkover J; Kurth H; Gralnek IM; Spiegel BM Am J Manag Care; 2005 Apr; 11(1 Suppl):S27-34. PubMed ID: 15926761 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]